EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Coreline Soft, Co., Ltd. (384470) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Coreline Soft, Co., Ltd. KRW 428, price KRW 2,630, upside -83.7%, quality 13 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

CS Thin data Sep 24, 2026

Coreline Soft, Co., Ltd.

384470 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 428.24 KRW · Strongly overvalued (−83.7%)
!Quality 13/100
!Weak Growth (revenue 3y +1.5 %/yr)
!Moderate debt · negative free cash flow
!Trails peers (1/6)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Coreline Soft, Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

37,048 KRW 2,310 KRW Fair Value 428.24 KRW Sep 2023 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

36‑month range 2,310 KRW – 37,048 KRW · fair‑value band 282.64 KRW – 535.30 KRW · the 2,630 KRW price screens above the 428.24 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Coreline Soft, Co. in your weekly email

Every Wednesday you see whether Coreline Soft, Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Coreline Soft Co., Ltd. develops medical software to provide diagnosis and image solution for lung diseases. It offers AVIEW Metric-Lung, a quantitative image biomarker software of COPD using chest CT images; AVIEW Modeler, a three-dimensional (3D) modeling software for 3D printing; and AVIEW Research, a software for medical research data management.

Show more

Coreline Soft Co., Ltd. develops medical software to provide diagnosis and image solution for lung diseases. It offers AVIEW Metric-Lung, a quantitative image biomarker software of COPD using chest CT images; AVIEW Modeler, a three-dimensional (3D) modeling software for 3D printing; and AVIEW Research, a software for medical research data management. The company was founded in 2012 and is based in Seoul, South Korea.

Stock analysis

Coreline Soft, Co., Ltd. (384470) currently trades at 2,630 KRW, while our model-based Fair Value estimate is 428.24 KRW, 83.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 282.64 KRW (bear) to 535.30 KRW (bull), the price of 2,630 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 13/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Coreline Soft, Co., Ltd. reported revenue of 4.3B KRW in FY2025 versus 2.2B KRW in FY2021, a compound +18.7%/yr. Reported net income was −14.5B KRW in FY2025.

Key figures

Market cap 51.8B KRW (≈ $38.6M) · P/S ratio 11.0 · Net margin −292% · Return on equity −137% · Return on assets (EBIT) −78.7% · Operating margin −239% · Revenue (TTM) 4.7B KRW · Revenue growth (YoY) +48.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 44% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −84%, 384470 screens richer than that median.

Fair Value models

Bear 282.64 KRW Fair Value 428.24 KRW Bull 535.30 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 506.29 KRW 678.43 KRW 1,013 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 506.29 KRW 678.43 KRW 1,013 KRW 54

Open the full fair value analysis →

Notify me when 384470 reaches fair value

Put 384470 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 13/100

Of which business quality 17 · Market factors (momentum, volatility) 24

Profitability 4
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 7
Earnings quality: real cash, not paper profit
Fin. Strength 28
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 52
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+9.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−341.0% (2021) → −313.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

384470 screens overvalued: fair value 84% below the price. Compare with Thermo Fisher Scientific Inc →

Compare Coreline Soft, Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 129 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 17 · Bottom 25%
Fair Value upside −83.7% · Bottom 25%
Profitability
Return on assets −21.1% · Bottom 25%
Growth and dividend
Revenue growth 48.7% · Top 25%
Balance sheet
Debt / equity 0.60× · Highest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)0 · sector 10
HEALTH (low debt)70 · sector 93
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $675.05 $686.04 +2%
Danaher Corporation DHR $221.55 $209.18 −6%
WuXi AppTec Co 603259 ¥162.40 ¥178.64 +10%
Agilent Technologies, Inc A $175.03 $64.17 −63%
Lonza Group LONN CHF 565.60 CHF 151.69 −73%
IQVIA Holdings IQV $270.37 $297.41 +10%
Waters Corporation WAT $433.54 $106.46 −75%
Illumina, Inc ILMN $271.90 $295.60 +9%
IDEXX Laboratories, Inc IDXX $533.44 $495.84 −7%
Mettler-Toledo International Inc MTD $1,512 $644.24 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Coreline Soft, Co., Ltd. · Fair Value
428.24 KRW −84%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Coreline Soft, Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/384470

Frequently asked questions

Is Coreline Soft, Co., Ltd. (384470) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 428.24 KRW versus a price of 2,630 KRW, about −84% upside (overvalued).
What is the fair value of 384470?
Our model-based fair value for Coreline Soft, Co., Ltd. is 428.24 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,630 KRW.
What is the quality score of 384470?
Coreline Soft, Co., Ltd. has a Quality Score of 13/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Coreline Soft, Co., Ltd. (384470)?
Our model-based price target is the fair value of 428.24 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 282.64 KRW, optimistic scenario 535.30 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Coreline Soft, Co., Ltd. stock forecast for 2026?
Our models put fair value at 428.24 KRW, about −84% upside versus a price of 2,630 KRW (overvalued). Cautious scenario 282.64 KRW, optimistic scenario 535.30 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Coreline Soft, Co., Ltd. (384470)?
Coreline Soft, Co., Ltd. reported trailing-twelve-month revenue of about 4.7B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Coreline Soft, Co., Ltd. (384470)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Coreline Soft, Co., Ltd. it is 428.24 KRW per share (as of Sep 24, 2026), against a price of 2,630 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Coreline Soft, Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 384470 trades above its calculated fair value: price 2,630 KRW, fair value 428.24 KRW, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 384470?
No. The price is what the market pays today (2,630 KRW); the fair value is what the company's own numbers justify (428.24 KRW). For Coreline Soft, Co., Ltd. the two are 2,202 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Coreline Soft, Co., Ltd. worth?
The market values Coreline Soft, Co., Ltd. at about 51.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,630 KRW; our models calculate a fair value of 428.24 KRW per share.
What do the bullish and bearish scenarios say about 384470?
Our models span a range for Coreline Soft, Co., Ltd.: cautious scenario 282.64 KRW, base 428.24 KRW, optimistic 535.30 KRW per share (as of Sep 24, 2026, price 2,630 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Coreline Soft, Co., Ltd. (384470)?
Balance-sheet figures for Coreline Soft, Co., Ltd. (as of Sep 24, 2026): return on equity −137.2%, debt of 0.60 per unit of equity. They feed the Quality Score of 13/100, which measures business quality independently of the share price.
How far is 384470 from its 52-week high?
Coreline Soft, Co., Ltd. trades at 2,630 KRW, about 44% below its 52-week high of 4,715 KRW and 14% above the low of 2,310 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 428.24 KRW is for.
Which stocks are comparable to Coreline Soft, Co., Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Coreline Soft, Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 2,630 KRW, calculated fair value 428.24 KRW (−84%), Quality Score 13/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 384470 calculated?
We run Coreline Soft, Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 428.24 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Coreline Soft, Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Coreline Soft, Co., Ltd. (384470)?
The closing price on Oct 2, 2026 was 2,630 KRW. Our model-based fair value is 428.24 KRW, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Coreline Soft, Co., Ltd. right now?
The price sits above even our optimistic bull case (535.30 KRW). The favourable scenario is already priced in. Weak quality (13/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (282.64 KRW to 535.30 KRW) leaves room in how you read the outcome.

Key figures of Coreline Soft, Co., Ltd.

How large is the market capitalisation of Coreline Soft, Co., Ltd. (384470)?
The market capitalisation of Coreline Soft, Co., Ltd. is 51.8B KRW (≈ $38.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Coreline Soft, Co., Ltd. (384470)?
The price-to-sales ratio of Coreline Soft, Co., Ltd. is 11.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Coreline Soft, Co., Ltd. (384470)?
The net margin of Coreline Soft, Co., Ltd. is −292% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Coreline Soft, Co., Ltd. (384470)?
The return on equity (ROE) of Coreline Soft, Co., Ltd. is −137% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Coreline Soft, Co., Ltd. (384470)?
On an EBIT basis the return on assets of Coreline Soft, Co., Ltd. is −78.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Coreline Soft, Co., Ltd. (384470)?
The operating margin of Coreline Soft, Co., Ltd. is −239% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Coreline Soft, Co., Ltd. (384470)?
Revenue at Coreline Soft, Co., Ltd. is growing +48.7% versus a year earlier (3y avg +1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Coreline Soft, Co., Ltd. (384470) generate?
The free cash flow of Coreline Soft, Co., Ltd. is −15.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Coreline Soft, Co., Ltd. (384470) carry?
The net debt of Coreline Soft, Co., Ltd. is 11.0B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Coreline Soft, Co., Ltd. in the live analysis

One click puts Coreline Soft, Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.